Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer

Oncologist

Volumn 16, Issue 9, 2011, Pages 1307-1315

  Yu, Joanne L ^a   Simmons, Christine ^b   Charles Victor, J ^a   Han, Dolly ^b   Hogeveen, Sophie ^b   Leighl, Natasha ^a   Verma, Sunil ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Metastatic; Non small cell lung cancer; Stage iv; Survival; Systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PEMETREXED; VASCULOTROPIN INHIBITOR;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80053197345     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0079     Document Type: Article

References (22)

1. Altekruse SF, Kosary CL, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute, based on November 2009 SEER data submission, posted to the SEER Web site, 2010. Available at http://seer.cancer.gov/csr/1975_2007/, accessed February 27, 2011.
2. Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 1993;342:19-21.
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. NEngl J Med 2002; 346:92-98.
4. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
5. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
6. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of do-cetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
7. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
8. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cis-platin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
10. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003; 21:2237-2246.
11. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
12. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with be-vacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
13. Lewis JH, Kilgore ML, Goldman DP et al. Participationof patients 65years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389.
14. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: A review of the evidence. Chest 2005;128:947-957.
15. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
16. Moore R, Doherty D, Chamberlain R et al. Sex differences in survival in non-small cell lung cancer patients 1974 -1998. Acta Oncol 2004;43: 57-64.
17. Patel JD, Bach PB, Kris MG. Lung cancer in US women: A contemporary epidemic. JAMA 2004;291:1763-1768.
18. al-Kattan K, Sepsas E, Townsend ER et al. Factors affecting long term survival following resection for lung cancer. Thorax 1996;51:1266-1269.
19. Hespanhol V, Queiroga H, Magalhaes A et al. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995;13:253-267.
20. Rasco DW, Yan J, Xie Y et al. Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-1535.
21. Wassenaar TR, Eickhoff JC, Jarzemsky DR et al. Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer. J Thorac Oncol 2007;2:722-728.
22. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit: The role of population-based outcome studies. JAMA 2008;300: 2177-2179.